Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Incyte Corporation.

Management of MF and PV for Today and Tomorrow: Navigating Novel Approaches to Improve Patient Care

Release Date: October 26, 2020
Expiration Date: October 26, 2021

Activity Overview

Patients with myeloproliferative neoplasms (MPNs) like myelofibrosis (MF) and polycythemia vera (PV) have historically had few treatments options that could modify the disease course to improve symptoms and overall survival. Clinicians need to remain updated on recent advances in the field so they can rapidly integrate emerging treatment options and principles into routine management.
This on-demand symposium is designed to provide participants with up-to-date knowledge regarding risk stratification, current management, and the potential role of emerging treatment options for MF and PV, reinforced by case scenarios discussed with the expert faculty panel. The overall goal of this program is to help participants make informed treatment decisions for patients with MPNs, while managing the treatment- and disease-related complications that arise from these malignancies.
This educational activity is an archive of a live virtual symposium held on October 7, 2020.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients with MPNs. Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of MPNs will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss risk-stratification and prognostic criteria used to assess patients with MF and PV
  • Review current treatment strategies as well as efficacy and safety data for agents approved for the management of MF and PV
  • Review data from ongoing clinical trials and discuss their impact on emerging treatment strategies for patients with MF and PV
  • Outline strategies for managing disease-related symptoms and identifying and managing treatment-related toxicities

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Ruben A. Mesa, MD, FACP
Ruben A. Mesa, MD, FACP
Mays Family Foundation Distinguished University Presidential Chair Professor of Medicine
Director UT Health San Antonio MD Anderson Cancer Center
San Antonio, TX

Disclosures: Grant Research Support: Celgene, CTI BioPharma, Image Pharmaceuticals, Incyte Corporation; Consultant: Blueprint Medicines, Bristol Myers Squibb, Novartis, Protagonist Therapeutics, SierraOne.

John Mascarenhas, MD
John Mascarenhas, MD
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Acute Leukemia Program
Leader of Clinical Investigation
Myeloproliferative Disorders Program
Tisch Cancer Institute Mount Sinai
New York, NY

Disclosures: Grant Research Support: CTI BioPharma, Forbius, Incyte Corporation, Janssen Pharmaceuticals, Kartos Therapeutics, Merck and Company, Novartis, Promedior, PharmaEssentia, Roche; Consultant: Celgene, Constellation Pharmaceuticals, Galecto, Geron Corporation, Kartos Therapeutics, PharmaEssentia, Prelude Therapeutics.

Laura Michaelis, MD
Laura Michaelis, MD
Associate Professor
Cancer Center – Froedtert Hospital
Medical College of Wisconsin
Milwaukee, WI

Disclosures: Laura Michaelis, MD, has no relevant financial relationships with commercial interests to disclose.

Ann Mullally, MD
Ann Mullally, MD
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: Grant Research Support: Actuate Therapeutics, Janssen Pharmaceuticals; Consultant: Janssen Pharmaceuticals; Speakers Bureau: Blueprint Medicines, Incyte Corporation, Roche.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By